Wedbush Reiterates an 'Outperform' on Biodel (BIOD); Comments on VIAjectT
More News related to BIOD
- Wedbush Reiterates an 'Outperform' on Biodel (BIOD); Comments on VIAjectT
- Unusual 11 Mid-Day Movers 3/25: CBG, MIC, JBL, HW Higher; DRYS, AIG, AMN, FTBK Lower
- Morning Movers 3/25: CBG, BIOD, ACAS, BBI, AMD Higher; DRYS, SOLF, STZ, CYPB, DSW Lower
- Biodel (BIOD) Plans to Submit NDA for VIAject(R) to FDA
- Wedbush Morgan Reiterates a 'Buy' on Biodel (BIOD)
More News related to Analyst Comments
- After-Hours Movers 11/30: GES, ALTR Higher; NLST, CUTR, LTON, OVTI Lower
- Trading Radar for 12/1: Staples (SPLS), Universal Tech (UTI), Beacon Roofing (BECN) Report
- Unusual 11 Mid-Day Movers 11/30: SOMX, CLWT, KBX, CSGS Higher; AIG, BGP, BONT, HEB Lower
- Notable ETF Movers: SLX, EWJ, USO Higher; UNG, XRT Lower
- Best of the Web 11/30: Some Banks So Bad Buyers Won't Touch 'Em, Risky Bets Hurt Harvard, Eurozone Inflation Turns Positive
Wedbush reiterates an Outperform rating on Biodel (Nasdaq: BIOD). Price target $17.
Wedbush analyst says, "VIAjectT ultra-rapid acting mealtime insulin was identified as a likely candidate to fill the market need for faster acting insulin. Two VIAjectT poster presentations extend upon previously reported data. We believe the FDA will accept the VIAjectT NDA filing in Q1 2010 and approve it between Q4 2010 and H1 2011."
To see more analyst ratings on BIOD Click Here.
Biodel, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis in the United States.
Related Categories
Analyst CommentsStocks Mentioned
+0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
